VivoSeq
Other

Otitis Media

20

Pipeline Programs↗

1

Active Trials↗

12

Companies Involved↗

Otitis media is an emerging landscape with 20 programs across 12 companies. The most active players are Portuguese Oncology Institute, Coimbra, Sanofi, Par Pharmaceutical, Inc.. 7 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

71/100

Attrition Rate

28/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Portuguese Oncology Institute, Coimbra

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 3P

Par Pharmaceutical, Inc.

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3GSK logo

GSK

2 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

22 of 23 classified programs — the dominant modality here.

4%ALL OTHERSVaccine14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed12 · 67%
Terminated4 · 22%
Withdrawn1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

Utility of Advanced Ultrasound Otoscope In The Diagnosis of Acute Otitis Media
Active, not recruiting·BBaylor College of Medicine·N/A·NCT06429709·300 enrolled
Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) - Study 2
Completed·AAlcon Research·Phase 3·NCT02436304·404 enrolled
Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes
Completed·OOtonomy, Inc.·Phase 3·NCT02600559·501 enrolled
Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media
Completed·UUMC Utrecht·N/A·NCT00189098·101 enrolled
Homeopathic Ear Drops for Otitis Media Study
Completed·UUniversity of Washington·N/A·NCT01003210·210 enrolled
Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)
Completed·GSK logoGSK·N/A·NCT01406275·363 enrolled
Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)
Completed·AAlcon Research·Phase 3·NCT02432105·470 enrolled
Ear Drops for Children With Otitis Media
Completed·UUniversity of Washington·N/A·NCT00622518·119 enrolled
Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
Completed·MMayo Clinic·Phase 3·NCT00279916·91 enrolled
Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children
Completed·MMenzies School of Health Research·Phase 4·NCT00539149·126 enrolled
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
Completed·AAnabio R&D·N/A·NCT05804123·175 enrolled
Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)
Completed·AAlcon Research·Phase 1·NCT02539654·14 enrolled
Maternal Immunization To Prevent Infant Otitis Media
Completed·National Institute on Deafness and Other Communication Disorders (NIDCD)·Phase 1/2·NCT00617682·153 enrolled
A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
Terminated·GSK logoGSK·Phase 3·NCT00119743·5,000 enrolled
TELI COM - Telithromycin in Children With Otitis Media
Terminated·Sanofi logoSanofi·Phase 3·NCT00315003·1,500 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)